AFC-HD AMS Life Science Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended November 2016; Provides Consolidated Earnings Guidance for the Six Months Ending February 2017 and Year Ending August 31, 2017
January 10, 2017 at 08:40 pm IST
Share
AFC-HD AMS Life Science Co., Ltd. reported consolidated earnings results for the first quarter ended November 2016. For the quarter, the company reported net sales of JPY 3,608 million against JPY 3,848 million a year ago. Operating income was JPY 252 million against JPY 344 million a year ago. Ordinary income was JPY 248 million against JPY 327 million a year ago. Profit attributable to owners of parent was JPY 106 million or JPY 8.80 per basic share against JPY 220 million or JPY 18.25 per diluted share a year ago.
The company provided consolidated earnings guidance for the six months ending February 2017 and year ending August 31, 2017. For the six months, the company expects net sales of JPY 7,400 million, operating income of JPY 500 million, ordinary income of JPY 470 million and profit attributable to owners of parent of JPY 200 million or JPY 16.51 per basic share.
For the year ending August 31, 2017, the company expects net sales of JPY 15,000 million, operating income of JPY 1,050 million, ordinary income of JPY 1,000 million and profit attributable to owners of parent of JPY 500 million or JPY 41.29 per basic share.
AFC-HD AMS Life Science Co Ltd is a Japan-based company mainly engaged in the development of the healthcare business and the pharmaceutical business. The Company is engaged in the research and development, product design, manufacture and sale of health foods and cosmetics, manufacture and sale of Chinese medicine medicines, general medicines, generic medicines, healthcare products, the sale of natural foods, as well as planning of health information programs. The Company operates in two business segments. The Healthcare segment is engaged in the manufacture and sale of health foods and cosmetics, as well as the provision of original equipment manufacturers (OEM). The Pharmaceutical segment is engaged in the manufacture and sale of ethical drugs and over-the-counter drugs, as well as the sale of generic drugs. The Company is also engaged in the management of restaurants through subsidiary.
AFC-HD AMS Life Science Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended November 2016; Provides Consolidated Earnings Guidance for the Six Months Ending February 2017 and Year Ending August 31, 2017
AFC-HD AMS LIFE SCIENCE CO., LTD. 
